In tumors such as NSCLC 10 and ccRCC 11, individuals with somatic PBRM1 mutations had upregulated treatment sensitivity to PD1/PDL1 inhibitors. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.